The trend in the price decline should not be put into question for stocks in Bayer over the coming trading sessions given the current chart pattern. Investors should open a short trade and target the € 88.05.
For a short-term investment strategy, the company has poor fundamentals.
The share is getting closer to its long-term support in weekly data, at EUR 88.91, which offers good timing for buyers.
The close medium term support offers good timing for purchasing the stock.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
This company will be of major interest to investors in search of a high dividend stock.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
Over the last seven days, analysts have been revising upwards their EPS estimates for the company.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The company is in debt and has limited leeway for investment
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
For the past year, analysts have significantly revised downwards their profit estimates.